Argentina 
Asia-Pacific 
Austria 
Brazil 
England 
Germany 
Hong Kong 
Malaysia 
Netherlands 
Poland 
Switzerland 
France 
The TRB France website showcases two decades of excellence in hyaluronic acid solutions.
It is with great pleasure that we celebrate the remarkable milestone of two decades of TRB France. We stand as one of the first companies in France to introduce intra-articular injections for osteoarthritis and ophthalmic drops containing hyaluronic acid for dry eyes. TRB Chemedica France, a subsidiary of the Swiss biotechnology group TRB Chemedica International, specializing in hyaluronic acid solutions for ophthalmology, rheumatology, orthopedics, and sports medicine, is proud to announce the launch of its updated website.
For over 20 years, TRB France has consistently developed and marketed hyaluronic acid-based solutions for ophthalmic and intra-articular use. Our range of products in the fields of rheumatology, orthopedics, and sports medicine includes OSTENIL® and VISCOSEAL®, both based on hyaluronic acid derived from fermentation, designed for intra-articular injections to combat osteoarthritis.
In the realm of ophthalmology, our HYLOVIS® product line, also based on hyaluronic acid from fermentation, is tailored for treating symptoms of dry eye and ocular surface lesions.
Our expert team of 25 dedicated professionals is committed to listening to healthcare professionals and their patients, ensuring that our products meet the highest standards of quality and efficacy.
Explore our website today to learn more about our products and the difference they can make in the fields of ophthalmology, rheumatology, orthopedics, and sports medicine.
Celebrate Pharma Innovation at CPHI Barcelona 2023
Join TRB at CPHI Barcelona 2023 from October 24 to 26
TRB Chemedica is set to attend the upcoming CPhI Worldwide Congress, a premier international event for the pharmaceutical industry, to showcase our range of high-quality pharmaceutical products and strong distribution network.
As a long-term manufacturer of Hyaluronic Acid, Diacerein and GM1 Ganglioside products, we strive to provide patients across the globe the opportunity to access our products. Our enduring and robust partnerships with well-established agents ensure our presence in over 70 countries. However, we are always looking to expand our network even further. We invite you to check out our interactive map to see if we are distributed in your country.
Moreover, our expertise in manufacturing, promoting, distributing and selling pharmaceutical products in the therapeutic areas of rheumatology, ophthalmology and neurology pushes us to always look for additional innovative solutions for patients.
The CPHI Worldwide Congress will offer an excellent opportunity for prospective collaborators and distributors to engage with us, learn about our products, and discuss potential partnerships so please feel free to visit us at booth 2T69.
Join us at the International Symposium on Intra Articular Treatment in Athens
We are excited to announce that we will be attending the ISIAT Congress 2023, the international symposium for ultrasound-guided intra-articular treatment, and we are looking forward to sharing our latest research with the global community.
The congress will be held in Athens, Greece from October 5-7, 2023. This will be the opportunity to present the preliminary results of our latest study evaluating the effectiveness of hyaluronic acid and mannitol to relieve symptoms in hip osteoarthritis. We will also be attending the scientific sessions and networking with other experts in the field.
We invite you to explore our Rheumatology webpage, where you can delve into our dedication to advancing hyaluronic acid-based treatments for rheumatology and tendinopathy. Discover how we’re reshaping these fields with innovative approaches.
We look forward to meeting you in Athens and on our webpage!
We are proudly sponsoring the 2023 OARSI Conference in Denver to advance osteoarthritis treatment and prevention
At TRB Chemedica, we are committed to advancing the field of osteoarthritis treatment by researching, developing, manufacturing, and marketing various molecules, such as hyaluronic acid and diacerein, to manage osteoarthritis-induced pain.
As osteoarthritis is one of our areas of focus, we are pleased to announce our sponsorship of this year’s Osteoarthritis Research Society International (OARSI) conference in Denver, which is dedicated to advancing prevention and treatment of osteoarthritis, and thus support their mission.
We are pleased to participate in World Arthritis Day
World Arthritis Day, referred to as WAD, aims at increasing disease awareness and knowledge on rheumatological conditions around the world. Current estimates list more than 200 rheumatic and musculoskeletal diseases (RMD), but their burden is largely underestimated by the general population. Consequently, a large proportion of patients are either not diagnosed or wait for extended periods of time before consulting their healthcare professionals.
More than 100.000.000 people worldwide suffer from rheumatological symptoms. These symptoms directly impact the quality of life of the patients and their professional activity. The inability to work reduces individuals’ self-esteem and increases their dependence on social assistance, family and friends.
Medical education has for a long time considered RMDs as second priority conditions, which means that symptoms might go unnoticed, misdiagnosed, or mistreated if people don’t have access to rheumatologists, nurses, physical therapists, or other healthcare professionals specifically trained in the field of RMD. As a result, people living with a rheumatic or musculoskeletal disease often have to face their condition alone and are lacking information on their symptoms, diagnosis and treatment options.
World Arthritis Day is intended to raise awareness on the existence and impact of RMD worldwide. This Day is an opportunity for all communities around the world to come together and speak with one voice to bring the much-needed messages to all audiences.
Over the past 20 years, TRB Chemedica has focused its rheumatological activities on osteoarthritis, the most prevalent joint disorder especially in middle-aged and elderly people.
Celebrating 20 years of healthcare excellence in the United Kingdom!
We are proud to announce the 20th anniversary of TRB UK! Responsible for marketing our rheumatology and ophthalmology product ranges in the UK and Ireland since 2002, TRB UK is an ISO 9001 certified company, an achievement that demonstrates our commitment to patients and healthcare professionals and our dedication to quality.
Join us at the European Society of Cataract and Refractive Surgeons Congress
Visit us at the 40th ESCRS Congress in Milan. We look forward to welcoming you at our booth B40 from September 16 to 20, 2022.
